Danish company, Genmab A/S (CPH: GEN) has initiated a Phase I/II study of HuMax- EGFr™ (zalutumumab) in combination with chemo-radiation as a first line treatment of head and neck cancer.
The said clinical study that will include a total of 36 patients suffering from advanced squamous cell carcinoma of the head and neck (SCCHN), is an open label study designed with an initial dose- Find more details from the press release. 
escalation part and a subsequent parallel group design: where a three dose levels of HuMax-EGFr™ will be tested in combination with conventional fractionated radiotherapy and cisplatin; and HuMax-EGFr™ will be tested in combination with cisplatin and three different regimes of accelerated radiotherapy, respectively.
Comment Preview